Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. Akebia's lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB-6548 is being developed as a once-daily oral therapy which works through the inhibition of hypoxia-inducible factor prolyl hydroxylase, leading to stabilization and increased levels of HIFα and therefore improved production of hemoglobin and red blood cells.
Cambridge, US
63 (est)+54%
Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, US

Akebia Therapeutics Locations

Cambridge, US

Akebia Therapeutics Metrics

Akebia Therapeutics Summary

Market capitalization

$182 M

Closing share price

Akebia Therapeutics's current market capitalization is $182 M.

Akebia Therapeutics Market Value History

We estimate that Akebia Therapeutics's current employees are approximately 24% female and 76% male.

Akebia Therapeutics Online Presence

Akebia Therapeutics News

Akebia Therapeutics Company Life

You may also be interested in